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High-fat diets lead to obesity, inflammation, and dysglycemia. 12-Lipoxygenase (12-LO) is activated by high-fat diets and cata-
lyzes the oxygenation of cellular arachidonic acid to form proinflammatory intermediates. We hypothesized that 12-LO in the
pancreatic islet is sufficient to cause dysglycemia in the setting of high-fat feeding. To test this, we generated pancreas-specific
12-LO knockout mice and studied their metabolic andmolecular adaptations to high-fat diets. Whereas knockout mice and con-
trol littermates displayed identical weight gain, body fat distribution, andmacrophage infiltration into fat, knockout mice exhib-
ited greater adaptive islet hyperplasia, improved insulin secretion, and complete protection from dysglycemia. At the molecular
level, 12-LO deletion resulted in increases in islet antioxidant enzymes Sod1 and Gpx1 in response to high-fat feeding. The ab-
sence or inhibition of 12-LO led to increases in nuclear Nrf2, a transcription factor responsible for activation of genes encoding
antioxidant enzymes. Our data reveal a novel pathway in which islet 12-LO suppresses antioxidant enzymes and prevents the
adaptive islet responses in the setting of high-fat diets.
Obesity, typically a result of diets high in saturated fat content,is directly correlated to insulin resistance and prediabetes.
Macrovascular disease consequences, including stroke, myocar-
dial infarction, and mortality increase even as blood sugars rise in
the prediabetic phase (1), thus emphasizing the perils of glycemic
dysregulation in the absence of frank diabetes. High-fat diets
(HFDs) and their consequent insulin resistance lead to adaptive
islet hyperplasia, in which basal secretion of insulin is increased in
an attempt to compensate for insulin resistance (2). However, this
compensatory mechanism can eventually fail in the face of pro-
longed insulin resistance. Inflammation and oxidative stress are
major factors thought to contribute to dysfunction of cells in the
setting of insulin resistance (3, 4). In this regard,  cells have low
expression and activity levels of the antioxidant enzymes com-
pared to other metabolic tissues (5), and the pathway(s) that en-
dogenously suppresses production of these antioxidant enzymes
in the  cell remains unclear.
The lipoxygenases represent a group of enzymes that catalyzes
the oxygenation of polyunsaturated fatty acids to form inflamma-
tory lipid intermediates, which have been shown to contribute to
oxidative stress (6). In the mouse, 12-lipoxygenase (12-LO) is ex-
pressed in several cell types, including macrophages, white adi-
pocytes, and pancreatic islets (7). 12-LO oxygenates membrane-
derived arachidonic acid primarily at the 12-position carbon atom
to form12-hydroperoxyeicosatetraenoic acid (12-HPETE),which
is then converted to the more stable form 12-hydroxyeicosatetra-
enoic acid (12-HETE) (7). The role of 12-LO in the setting of
HFDs and obesity has been studied primarily in the context of
whole-body 12-LO knockout mice. Recent studies showed that
12-LO knockout mice fed a HFD exhibit reduced macrophage
infiltration into adipose tissue, reduced insulin resistance, en-
hanced cell function, and improved glucose tolerance compared
to controls (8, 9). Tissue-specific deletion of 12-LO driven by the
aP2-Cre transgene in mice led to similar protection from HFD-
induced glucose intolerance (10), suggesting that the effects seen
in the whole-body knockout might be attributable to effects of
12-LO deletion in adipocytes or macrophages. Although 12-LO
expression in pancreatic islets is low to undetectable at baseline, its
expression in islet  cells is increased in the setting of metabolic
stresses, such as hyperglycemia, cytokine-mediated damage, and
partial pancreatectomy (11–13). In none of the knockout animal
models to date is it clear whether 12-LO in the islet could contrib-
ute to insulin secretory defects.
To address more directly the actions of 12-LO in the islet, we
generatedmice with specific deletion of 12-LO in islets and exam-
ined their response to cytokines and obesity-induced glucose in-
tolerance. We show that deletion of 12-LO in the islet protected
mice from glucose intolerance seen in both multiple low doses of
streptozotocin (STZ) and from HFD feeding. Deletion of 12-LO
increased antioxidant enzyme levels in islets and decreased islet
oxidative stress, in part, through increased nuclear translocation
of Nrf2. Our results indicate for the first time that 12-LO plays an
important role in metabolic stress-induced dysfunction in islet 
cells, and 12-LO activity in the islet itself is sufficient to induce
whole-body glucose intolerance under conditions of HFD con-
sumption.
MATERIALS AND METHODS
Animals and genotyping. Experiments involving mice were performed
under protocols approved by the Indiana University Institutional
Animal Care and Use Committee. CD1 mice (for procurement of
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mouse islets) were purchased from Charles River Laboratories.
Alox15Loxp/ mice, in which Cre recombinase recognition sequences
(Loxp) flank exons 2 to 5, were generated by Ozgene on a C57BL/6
genetic background. Alox15Loxp/ mice were bred to Pdx1-Cre trans-
genic mice (14) to generate mice with a pancreas-specific knockout of
12-LO (Pdx1-Cre; Alox15Loxp/Loxp, referred to as pLO-KO mice).
Allele-specific genotypingwas performed by PCRusing primers flank-
ing the 5= LoxP site: 5=-CATGGGTTCTCTGCCTTAGTGG-3=, and 5=-T
CACCTCAACCAAGAGTGAGAGGG-3=. Using these primers, the wild-
type Alox15 allele generates an amplicon of 175 bp, and the mutant allele
generates an amplicon of 251 bp. For analysis of genomic recombination
in islets, hypothalamus, muscle, fat, and liver, DNA was extracted from
these tissues using a commercially available kit (Sigma) and subjected to
PCR using primers designed to amplify the recombined allele: 5=-TTTCC
CATCGTCCATCGTCCATCC-3= and 5=-TCCCTACTTGACCCAGACT
ACCAG-3=. The PCR product (173 bp) was analyzed using a 2% agarose
gel, and its identify was confirmed by automated sequencing.
HFD feeding and animal procedures. For experiments involving de-
fined diet feeding, 8-week-old male wild-type and pLO-KO mice were
placed on a normal chow diet (NCD) containing 18% kcal from fat, 58%
kcal from carbohydrate, and 24% kcal from protein (2018S, Harlan Lab-
oratories), or an HFD consisting of 42% kcal from fat, 43% kcal from
carbohydrate (mostly sucrose), and 15% kcal from protein (TD.88137,
Harlan Laboratories).
Blood glucose was measured weekly for 4 weeks using an AlphaTRAK
glucometer (Abbott Laboratories). Body weights were measured weekly.
Body composition wasmeasured by using dual energy X-ray absorptiom-
etry analysis (Lunar PIXImusII densitometer; GEMedical Systems). Glu-
cose-stimulated insulin secretion in vivo, glucose tolerance tests (GTTs),
and insulin tolerance tests were performed as described previously (15)
with the following modifications: for the GTTs mice were injected intra-
peritoneally with 2 g/kg glucose after an overnight fast, and for the insulin
tolerance testsmicewere injected intraperitoneallywith 0.75U/kg insulin.
For studies involving insulin signaling, mice were injected intraperitone-
ally with 10 U/kg regular human insulin or saline for 5 min prior to
euthanasia, as described previously (16).
Islets andassays.Mouse isletswere isolated fromcollagenase-digested
pancreas (17) and were allowed to recover overnight prior to experimen-
tation. Islets were treated with a mixture of cytokines (10 ng/ml tumor
necrosis factor alpha [TNF-], 100 ng/ml gamma interferon [IFN-], and
5 ng/ml interleukin-1 [IL-1]) or 100 nM 12-HETE for either 4 or 24 h.
Static glucose-stimulated insulin secretion assays using islets were per-
formed as previously described (15), and insulin released into themedium
was measured using a mouse insulin enzyme-linked immunosorbent as-
say (ELISA) kit (Alpco Diagnostics). 12-HETE released into the medium
wasmeasured by using a 12-HETE ELISA kit (Enzo Life Sciences). Insulin
in mouse serum was measured by using an ultrasensitive mouse insulin
ELISA kit (Crystal Chem), and serum proinsulin was measured using a
mouse proinsulin ELISA kit (ALPCODiagnostics), both according to the
manufacturer’s protocols. The preproinsulin unmethylation index from
mouse serum was performed as described previously (18). Reactive oxy-
gen species (ROS) were stained in isolated islets using CellROXDeep Red
reagent (Life Technologies) and counterstained with Hoechst dye.
Immunostaining andmorphometric assessment of cell area. Pan-
creata and adipose tissue from at least three different mice per group were
fixed in 4% paraformaldehyde, paraffin embedded, and sectioned onto
glass slides. The  cell area as a percentage of total pancreas area ( cell
area%)was calculated as previously detailed (19). Chop andKi67 staining
was quantified by counting the number of Chop and Ki67 nuclei in
insulin cells per islet. 12-LO, ROS, 4-HNE, GPx1, SOD1, and catalase
were quantified by measuring pixel density per insulin cell. Nrf2 was
quantified by measuring nuclear and cytoplasmic pixel density per insu-
lin cell. Images were acquired by using an Axio-Observer Z1 (Zeiss)
inverted fluorescence microscope or an LSM 700 (Zeiss) confocal
equipped with an Orca ER charge-coupled device camera (Hamamatsu).
Antibodies and immunoblots. Immunohistochemistry of pancreas
sections were performed using anti-insulin antibodies (sc-9168 [Santa
Cruz Biotechnology]; 1:250) and horseradish peroxidase-conjugated sec-
ondary antibodies (Vector Laboratories). Adipose tissue sections were
immunostained using anti-F4/80 antibodies (14-4801 [eBioscience];
1:100) and horseradish peroxidase-conjugated secondary antibodies
(Vector Laboratories). For immunofluorescence of pancreas sections,
sections were stained with anti-12-LO (sc-27357 [Santa Cruz Biotechnol-
ogy]; 1:100), anti-Ki67 (ab66155 [Abcam]; 1:200), anti-Chop antibody
(sc-575 [Santa Cruz Biotechnology]; 1:200), anti-4-HNE antibody
(Ab464545 [Abcam]; 1:100), anti-Gpx1 antibody (sc-22145 [Santa Cruz
Biotechnology]; 1:200), anti-Sod1 antibody (sc-11407 [Santa Cruz Bio-
technology]; 1:200), anticatalase antibody (sc-34285 [SantaCruz Biotech-
nology]; 1:200), anti-Nrf2 antibody (sc-722 [Santa Cruz Biotechnology];
1:200), and/or anti-insulin antibodies (Life Technologies; 1:250). Alexa
Fluor 568–donkey anti-rabbit antibody and Alexa Fluor 488–donkey
anti-guinea pig antibody were used as secondary antibodies (Invitrogen).
Whole-cell extracts from islets were resolved by electrophoresis on a 4
to 20% sodiumdodecyl sulfate-polyacrylamide gel, followed by immuno-
blotting with anti-phospho-Akt (9271 [Cell Signaling]),anti-Akt (2920
[Cell Signaling]), antiactin (691001 [ImmunO]), anti-histoneH3 (07-030
[Upstate]), anti-Nrf2 (sc-722 [Santa Cruz Biotechnology]), anti-Gpx1
(sc-22145 [Santa Cruz Biotechnology]), and anti-Chop (sc-575 [Santa
Cruz Biotechnology]) primary antibodies and fluorophore-labeled sec-
ondary antibodies. Immunoblots were visualized by using the LiCor Od-
yssey system (LiCor Biosciences).
Quantitative real-time reverse transcription-PCR (RT-PCR). Real-
time PCR from reverse-transcribed RNA was performed using SYBR
green technology and primers previously described as follows: Alox15
(20);Gpx1 and Sod1 (21);Catalase (22);Chop,Bip,Xbp1,Xbp1s, andNos2
(23); and Nfe212 (24).
Statistical analysis. All data are presented as means  the standard
errors of the mean. A Student t test was performed for comparisons in-
volving two conditions and a one-way analysis of variance (with a Dun-
nett’s post test) was performed for comparisons involving more than two
conditions. Area-under-the-curve analyses were performed using the
trapezoidmethod. GraphPad Prism (version 5.0) software was used for all
statistical analyses. P values of0.05 were considered significant.
RESULTS
Generation of pancreatic islet 12-LO knockout (pLO-KO)mice.
To obtain an islet-specific deletion of the mouse gene encoding
12-LO (Alox15), we first generated mice in which exons 2 to 5 of
an Alox15 allele were flanked by Cre recombinase recognition se-
quences (Loxp), as shown in Fig. S1A in the supplemental mate-
rial. The resultant mice were bred to homozygosity and then
crossed to mice harboring the Pdx1-Cre transgene to remove
12-LO at the inception of pancreas development (henceforth re-
ferred to as pLO-KO mice). Because 12-LO is absent in the exo-
crine pancreas (25) (see Fig. S2A in the supplemental material),
pLO-KOmice are essentially islet-specific 12-LO knockouts. PCR
genotyping was used to confirm mice of differing genotypes
(Alox15/, Alox15Loxp/, and Alox15Loxp/Loxp) (see Fig. S1B in the
supplemental material). Quantitative RT-PCR analysis showed
significant reduction of the mRNA encoding 12-LO in islets but
not in fat or liver; the hypothalamus does not exhibit detectable
levels of themRNA in control or pLO-KO animals (see Fig. S1C in
the supplemental material).
Islets from pLO-KOmice exhibit resistance to cytokine tox-
icity in vitro. Intraperitoneal GTTs were indistinguishable be-
tween 8-week-old pancreas-specific male and female pLO-KO
and heterozygous knockout (pLO-HET) mice compared to con-
trol littermates (Alox15Loxp/Loxp mice not carrying the Pdx-Cre
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transgene) (see Fig. S1D and E in the supplemental material).
Islets isolated from pLO-KO and control male mice exhibited
identical glucose-stimulated insulin secretion in vitro (see Fig. S1F
in the supplementalmaterial). These data, consistent with those of
the global 12-LO knockouts (26), suggest that the absence of
12-LO in pancreas has little or no impact on the development/
allocation of islet cell types and islet function or on glucose ho-
meostasis.
Most forms of diabetes involve proinflammatory cytokine-me-
diated dysfunction of islet  cells (27). In particular, it has been
shown that in mouse models of obesity and type 2 diabetes, eleva-
tions in levels of proinflammatory cytokines IL-1-, TNF-, and
IFN- occur (likely released from macrophages and adipose tis-
sue) (28–30). To determine whether deletion of 12-LO confers
resistance to proinflammatory cytokines, we next incubated islets
from pLO-KO mice or control littermates with a cocktail of pro-
inflammatory cytokines (IL-1, TNF-, and IFN-) in vitro at
concentrations previously used in the literature (19, 31). As shown
in Fig. S1F in the supplemental material, after 4 h of cytokine
exposure, islets fromboth control and pLO-KO animals exhibited
increased basal (low glucose) insulin secretion and diminished
stimulated (high glucose) insulin secretion compared to islets not
exposed to cytokines. However, after 24 h of cytokine treatment,
islets from pLO-KOmice exhibited relatively lower insulin secre-
tion at low glucose and greater insulin secretion at high glucose
compared to islets from control littermates (see Fig. S1F in the
supplementalmaterial). The resulting insulin stimulatory index at
24 h was unchanged in pLO-KO islets compared to 4 h, whereas
the index in control islets at 24 h continued to decline (Fig. 1A).
These data suggest that deletion of 12-LO from islets results in
delayed (4 h) protection from cytokine toxicity. To clarify the
mechanism underlying the role of 12-LO at 4 h versus 24 h of
FIG 1 Susceptibility of pLO-KO islets and mice to cytokine-induced dysfunction. (A) Insulin stimulatory index (ratio of insulin secretion at 2.5G:25G) from
islets isolated frommale control Alox15Loxp/Loxp (fl/fl) and pancreatic 12-LO knockout (pLO-KO) mice after 0, 4, and 24 h of cytokine treatment (n	 3 or 4 per
group); (B) 12-HETE secretion from isolated control and pLO-KO islets after 0, 4, and 24 h of cytokine treatment (n	 3 or 4 per group); (C) male control and
pLO-KOmice were subjected to multiple low-dose injections of STZ (55 mg/kg daily for 5 days), and random glucoses were monitored for 30 days (n	 5 or 6
animals per group); (D) glucose tolerance test at 10 days after the start of STZ injections (left panel) and the corresponding area under the curve (AUC) (right
panel) (n	 5 or 6 animals per group); (E) glucose tolerance test at 30 days after the start of STZ injections (left panel), and the corresponding AUC (right panel)
(n 	 5 or 6 animals per group); (F) representative images of pancreata immunostained for insulin (brown) and counterstained with hematoxylin (blue).
Magnification,
100. *, P 0.05 for the value compared to the corresponding control.
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cytokine treatment, we examined 12-HETE (the product of 12-LO
activity) secretion from islets. As shown in Fig. 1B, no 12-HETE
production was detected in control or pLO-KO islets after 4 h of
cytokine treatment. However, 12-HETE production was signifi-
cantly increased in control islets after 24 h of cytokine treatment
but not in pLO-KO islets (Fig. 1B). These data suggest that accu-
mulation of the downstream proinflammatory lipid product of
12-LO, 12-HETE, is correlated with the severe dysfunction of is-
lets seen after 24 h of cytokine exposure.
pLO-KOmice are protected fromglycemic deterioration fol-
lowing low-dose streptozotocin injections.To testwhether resis-
tance of pLO-KO islets to cytokine stress translates to resistance to
dysglycemia in vivo, we subjectedmale control and pLO-KOmice
to five daily low doses of STZ (55 mg/kg given intraperitoneally)
and monitored the blood glucose levels over the next 25 days. In
this model, the recruitment of dendritic cells/macrophages into
the vicinity of the islet causes the local release of proinflammatory
cytokines, which leads to islet dysfunction and eventual death (19,
32). Prior studies have shown that global 12-LO knockout mice
are protected from low-dose STZ treatment (26), but it remains
unclear whether this effect is secondary to loss of 12-LO in  cells
or immune cells. As shown in Fig. 1C, control mice developed
hyperglycemia (300 mg/dl) by day 10, which gradually wors-
ened over the next 20 days. In contrast, pLO-KOmice showed the
same initial hyperglycemia by day 10, but thereafter blood gluco-
ses remained stable. Intraperitoneal GTTs performed at day 10
demonstrated indistinguishable glucose tolerance between the
two groups of mice (Fig. 1D). However, consistent with the blood
glucose values at 25 days after the administration of STZ, glucose
tolerance of pLO-KO mice was significantly improved compared
to the control animals (Fig. 1E). Immunohistochemical analysis of
pancreata of STZ-treated mice at the end of the study revealed
significantly greater insulin staining intensity in pLO-KO mice
compared to control animals (Fig. 1F). These data suggest that the
absence of 12-LO specifically in the pancreas is sufficient to pro-
tect against the long-term deterioration of glycemic control with
multiple low-dose STZ.
pLO-KOmice are protected fromglycemic deterioration in a
model of obesity-induced  cell dysfunction. HFDs lead to po-
larization of adipose tissue macrophages to a more proinflamma-
tory phenotype, resulting in the release of inflammatory cytokines
that impair  cell function (33, 34). To test resistance of pLO-KO
islets to cytokine stress in vivo, we subjected pLO-KO mice and
control littermates (Alox15Loxp/Loxp animals) to HFD feeding. We
placed 8-week-old mice on either the Western HFD (42% kcal
from fat) or normal chow diet (NCD, 17% kcal from fat) for 20
weeks. At the end of the feeding, examination of pancreatic islets
revealed an increase in 12-LO staining in control animals placed
on a HFD compared to animals on a NCD, with no staining in
extra-islet tissues (see Fig. S2A in the supplemental material). As
expected, 12-LO immunoreactivity was significantly reduced in
the pLO-KO animals (see Fig. S2A and B in the supplemental
material). During the feeding study, pLO-KOmice gained equiv-
alent weight and percent fat mass compared to control mice on a
HFD, both parameters of which were greater than themice placed
on aNCD (see Fig. S2C andD in the supplementalmaterial). HFD
feeding, however, did not significantly alter lean bodymass in any
of the animals (see Fig. S2E in the supplemental material). Insulin
tolerance tests revealed that both control and pLO-KO mice ex-
hibited impairments in insulin sensitivity compared to animals on
a NCD (Fig. 2A). Similarly, insulin signaling measured by phos-
phorylated Akt in muscle was not different in HFD-fed pLO-KO
mice compared to controls (see Fig. S3A in the supplemental
material). Prior studies of HFD feeding of global 12-LO knock-
out mice revealed reductions in adipocyte size and infiltration
of adipocytes by macrophages compared to control mice (8, 9).
However, in HFD-fed pLO-KO mice, we observed no differ-
ences in adipocyte size or F4/80 macrophage infiltration into
adipocytes compared to control animals fed a HFD (see Fig.
S3B and C in the supplemental material). Collectively, these
data demonstrate that pancreas-specific knockout of 12-LO
did not affect cellular or whole-body insulin resistance, as ac-
quired during HFD feeding.
To assess glucose homeostasis, we next performed intraperito-
neal GTTs. As shown in Fig. 2B, whereas HFD-fed control mice
exhibited impaired glucose tolerance compared to those fedNCD,
pLO-KO mice fed a HFD displayed glucose tolerance that was
indistinguishable from those fed a NCD. Although HFD feeding
(and consequent insulin resistance) led to higher insulin levels
FIG 2 Effect of high-fat diet feeding on insulin sensitivity, glycemic control,
and insulin secretion. At 8 weeks of age, control (fl/fl) and pLO-KOmale mice
were placed on a normal chow diet (NCD) or a high-fat diet (HFD) for 20
weeks. (A) Insulin tolerance tests and corresponding area over the curve
(AOC) (n 	 4 to 8 animals per group); (B) glucose tolerance tests and the
corresponding AUC (n 	 4 to 8 animals per group); (C) insulin levels mea-
sured at the indicated times after intraperitoneal glucose injection and the
corresponding AUC (n 	 3 or 4 animals per group). *, P  0.05 for the
comparisons indicated.
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within the first 10min after glucose injections in both control and
pLO-KO animals, the insulin levels in pLO-KO animals were sig-
nificantly greater than in controlmice during this time frame (Fig.
2C). The greater insulin levels in HFD-fed pLO-KO animals sug-
gest that these animals have enhanced  cell insulin secretory
function, a finding consistent with our observations in vitro that
pLO-KO islets secretemore insulin in the face of proinflammatory
cytokines.
HFD-fed pLO-KO mice exhibit enhanced  cell mass and
reduced cell death. Improvements in insulin secretion inHFD-
fed pLO-KO mice led us to examine the morphology of islets. As
shown in Fig. 3A, the  cell area% (relative to the total pancreas
area) was greater in HFD-fed control and pLO-KO mice than in
their NCD-fed counterparts. However, the  cell area% of HFD-
fed pLO-KO animals was significantly higher than that of HFD-
fed control animals (Fig. 3A), a finding concordant with the
higher insulin levels observed in these animals. To determine
whether the increased  cell area% of HFD-fed pLO-KO animals
resulted from changes to  cell proliferation, pancreatic sections
were stained for Ki67. Both control and pLO-KO HFD-fed mice
had increased, Ki67/insulin compared to NCD-fed mice but
were undistinguishable from each other (Fig. 3B). Instead,  cell
death was reduced in pLO-KOmice, since unmethylated prepro-
insulin DNA in the serum (the “unmethylation index,” a specific
marker of  cell death) (18) was reduced in these mice compared
to controls (Fig. 3C). Interestingly, this reduction in  cell death
was associated with reductions in insulin/Chop cells in
pLO-KOmice (Fig. 3D), suggestive of reductions in endoplasmic
reticulum (ER) stress-induced apoptosis. Consistent with this
possibility, pLO-KOmice exhibited reductions in the proinsulin/
insulin ratio (Fig. 3E), whichmay be reflective of reducedER stress
(23).
12-LO deletion protects against chronic cytokine-induced
oxidative and ER stress in vitro. Because improved glucose tol-
erance in HFD-fed pLO-KOmice was attributable to improved
 cell function and survival, we next investigated signaling
pathways that contribute to  cell survival in these animals.
The 12-HETE and other lipid peroxides produced by 12-LO
leads to oxidative stress (35). Immunofluorescence analysis us-
ing a fluorescent dye-based free radical sensor (CellROX) dem-
onstrated an increase in ROS upon incubation of control islets
with cytokines for 24 h (Fig. 4). In contrast, ROS production
was almost completely blocked in pLO-KO islets upon incuba-
tion with cytokines for 24 h. Notably, this effect of cytokines
was reproduced upon incubation with 100 nM the 12-LO prod-
uct 12-HETE for 24 h regardless of genotype, suggesting that
cytokine-induced ROS production at 24 h may result from
downstream products of 12-LO activity. Because of low anti-
oxidant enzyme production, islet  cells have limited ability to
counter ROS production. As shown in Fig. 5A, incubation of
control mouse islets with cytokines for 24 h resulted in a reduc-
tion in the mRNA encoding glutathione peroxidase (Gpx1). In
contrast, cytokine incubation of pLO-KO islets for 24 h led to
an increase in Gpx1 levels. The reduction in Gpx1 mRNA by
cytokines was mimicked by the addition of 12-HETE, regard-
less of genotype (Fig. 5A). Figure 5B and C show that protein
levels of GPx1 by immunoblot paralleled the changes in mRNA
levels.
Oxidative stress is closely linked to activation of the unfolded
protein response (UPR) and ER stress, since increased oxidation
of proteins can lead to the misfolding of proteins in the ER lumen
(36). Figure 5D and E show that incubation of control islets with
cytokines for 24 h results in an increase inXbp1s andChopmRNA
levels, respectively, and that these increases were blunted in
FIG3 Effect of high-fat diet feeding on cell replication, survival, and function. At 8weeks of age, control (fl/fl) and pLO-KOmalemicewere placed on a normal
chow diet (NCD) or a high-fat diet (HFD) for 20 weeks. (A) Relative  cell area as a percentage of total pancreatic area after 20 weeks of feeding (n	 3 animals
per group); (B) Ki67/insulin cells as a percentage of total insulin cells in islets after 20 weeks of feeding (n	 3 animals per group); (C) serum unmethylation
index after 20 weeks of feeding (n	 3 animals per group); (D) Chop/insulin cells as a percentage of total insulin cells in islets after 20 weeks of feeding (n	
3 animals per group); (E) serum proinsulin to insulin ratio after 20 weeks of feeding (n	 4 animals per group). *, P 0.05 for the comparisons indicated.
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pLO-KO islets. Incubation with 100 nM 12-HETE produced in-
creases inXbp1s andChop similar to cytokines in both control and
pLO-KO islets, suggesting that the development of ER stress by
cytokines at 24 hmay be largelymediated by 12-LO products (Fig.
5D and E). Collectively, these data indicate that the increased ox-
idative stress of cytokines appears to be closely linked to ER stress
and that the absence of 12-LO in islets is partially protective
against these changes.
HFD-fed pLO-KO mice showed decreased islet oxidative
stress and increased antioxidant enzyme levels. The activation of
oxidative stress in cytokine-treated islets led us to explore whether
oxidative stress is correlated with islet dysfunction in HFD-fed mice
and whether deletion of 12-LO is protective. We costained pancreas
sections of NCD- andHFD-fedmice for insulin and 4-hydroxynon-
enal (4-HNE), a product of endogenous lipid peroxidation and a
marker of oxidative stress-induced cellular damage. Mice fed NCD
had little to no 4-HNE staining in  cells, whereas HFD-fed control
mice had intense 4-HNE staining (Fig. 6A). In contrast, HFD-fed
pLO-KO mice had little to no 4-HNE staining, similar to NCD-fed
mice (Fig. 6A). These data parallel findings from isolated islet studies
(Fig. 4), suggesting that the absence of 12-LO protects against the
development of oxidative stress.
To determine whether the reduction in apparent islet oxidative
stress inpLO-KOmice resulted fromincreases inantioxidantenzyme
levels, we next costained pancreatic sections for insulin and antioxi-
dant enzymes. The  cells of NCD-fed animals showed minimally
detectable levels of Gpx1 (Fig. 6B), superoxide dismutase (SOD1)
(Fig. 6C), and catalase (Fig. 6D). Whereas Gpx1 staining intensity
decreases slightly in cells uponHFD feeding in control mice, levels
increase substantially after HFD feeding in pLO-KOmice (Fig. 6B).
FIG 4 ROS production after cytokine exposure. Islets from 8-week-old control (fl/fl) and pLO-KO mouse islets were treated with or without cytokines (Cyto)
or with or without 12-hydroxyeicosotetranoic acid (12-HETE) for 24 h. Isolated islets were stained for ROS (red) and Hoechst (blue). Shown are representative
images (left panel) and pixel density of ROS staining (right panel). Magnification,
200. *, P 0.05 compared to the control in each group.
FIG 5 Expression of genes encoding antioxidant enzymes and ER stress markers in response to cytokine treatment. Islets from 8-week-old control (fl/fl) and
pLO-KOmice were isolated and treated with or without cytokines and with or without 12-HETE for 24 h and processed for RNA or protein (n	 3 per group).
(A) Relative levels ofGpx1mRNA in control (fl/fl) and pLO-KO islets (normalized toActbmRNA); (B) representative immunoblot for GPx1 protein and histone
3; (C) quantitation of immunoblots (B) for GPx1 protein normalized to histone 3 (n	 3); (D and E) relative levels of splicedXbp1 andChopmRNA, respectively
(normalized to Actb mRNA). *, P 0.05 for the comparisons shown.
Tersey et al.
3740 mcb.asm.org Molecular and Cellular Biology
Similar results were observed with SOD1 and catalase (Fig. 6C and
D), wherein staining intensities of these enzymes increased in
pLO-KOmice uponHFD feeding. Taken together, with the data ob-
tained from cytokine incubations in vitro, it appears that 12-LO pro-
motesoxidative stressbypreventingadaptive increases inantioxidant
enzymes in islet  cells.
12-LO inhibits nuclear accumulationof theNrf2 antioxidant
gene activator. The Nrf2 transcription factor is an important ac-
tivator of antioxidant genes, and the promoters of Gpx1 and Sod1
contain Nrf2 recognition sequences (37). To understand better
the mechanism for the increased antioxidant gene activity in
pLO-KO mice, we examined levels of Nrf2 protein and its corre-
sponding mRNA (Nfe212). As shown in Fig. 7A, treatment of
mouse islets with cytokines for 24 h resulted in a reduction in
Nfe212 mRNA levels, which were not only restored but increased
in islets isolated from pLO-KO mice. Incubation with 100 nM
12-HETE reduced Nfe212 mRNA in both control and pLO-KO
islets, suggesting that the negative effect of cytokines on Nfe212
transcription is mediated by 12-HETE. Immunoblots of islet cell
extract showed that Nrf2 protein levels paralleled the observed
transcript levels (Fig. 7B and C).
To determine whether the effects 12-LO deletion on Nrf2 are
observed in vivo, we costained pancreas sections from HFD-fed
mice. As shown in Fig. 7D and E, pLO-KO mice had increased
Nrf2 in the nuclear and perinuclear region compared to control
animals. Taken together, these data suggest that 12-LO and its
products, notably 12-HETE, inhibit activation and nuclear local-
ization of Nrf2 in the setting of cytokine-mediated stress.
FIG 6 Oxidative stress and antioxidant enzyme staining in islets after HFD feeding. Fixed pancreatic sections from control (fl/fl) and pLO-KOmice fed a normal
chow diet (NCD) or a high-fat diet (HFD) for 20 weeks were subjected to immunofluorescence staining. Shown are representative images (left panel) and the
pixel density (right panel) from analysis of at least three animals from each group stained for 4-hydroxynoneal (4-HNE, red) and insulin (green) (A), glutathione
peroxidase (GPx1, red) and insulin (green) (B), superoxide dismutase (SOD1, red) and insulin (green) (C), and catalase (Cat, red) and insulin (green) (D).
Magnification,
200. *, P 0.05 compared to the control in each group.
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DISCUSSION
Prediabetes is characterized by inflammation involving macro-
phages, adipose tissue, and the pancreatic islet (27). The enzyme
12-LO is expressed in key tissues involved inmetabolic homeosta-
sis—leukocytes, adipose tissue, and pancreatic islets—and is
thought to contribute to the inflammation and insulin resistance
seen in prediabetic states. Rodent and human pancreatic islets
have been shown to express 12-LO and its products in the context
of inflammation (35, 38, 39), but whether 12-LOplays an intrinsic
role in islet dysfunction duringHFD feeding in vivohas never been
addressed until the present study. To interrogate both a role and a
mechanism for islet-intrinsic 12-LO in the setting of insulin resis-
tance, we crossed Pdx1 promoter-driven Cre recombinase trans-
genic mice to Alox15 “floxed”mice. Pdx1-Cre is expressed in pan-
creatic progenitors beginning at embryonic day 9.0, and the
resultant mice from this cross are technically pancreas-specific
12-LO knockouts (pLO-KO). However, because 12-LO is absent
in pancreatic exocrine tissue (the present study and reference 25),
we considered these mice as islet-specific knockouts. We show
that pLO-KO mice gain weight normally on a chow diet and ex-
hibit no overt metabolic phenotype. Our data support whole-
body knockout studies that suggest that 12-LO is dispensable for
pancreas development and islet mass accrual and function post-
developmentally (26).
HFDs have been shown to provoke inflammation in both adi-
pose tissue and islets, in part through the recruitment of macro-
phages and their local release of proinflammatory cytokines (33).
We show here that pLO-KOmice exhibit improved glucose toler-
ance, with greater insulin secretion and  cell mass compared to
HFD-fed control littermates. Given the specificity of our knock-
out for the islet, we accordingly observed no differences in weight
gain and body fat distribution, adipocyte size, or macrophage in-
filtration into adipose tissue between control and pLO-KO ani-
mals. Importantly, no differences in insulin sensitivity (either by
ITT or phospho-Akt signaling in muscle) were observed between
control and pLO-KO mice, a finding that is also consistent with
the islet specificity of the knockout. We therefore conclude that
the improvement in glycemic control in pLO-KO animals is at-
tributable to an islet-intrinsic effect of 12-LO deletion. This con-
clusion is also consistent with the known specificity of the Pdx1-
Cre transgene for pancreas compared to adipose tissue,
macrophage, liver, and brain. Notably, a recent study demon-
strated expression of the Pdx1-Cre transgene in brain (40); how-
ever, based on genomic DNA analysis of Alox15 gene recombina-
tion, we did not observe evidence for recombination in brain
tissue from our animals.
To verify the resistance of pLO-KO-derived islets to inflamma-
tion, we performed cytokine incubation studies in vitro. Interest-
ingly, following an initial reduction in glucose-stimulated insulin
secretion (equivalent to that seen in control islets), pLO-KO islets
subsequently maintained their level of glucose responsiveness.
These findings were also reflected in the multiple low-dose STZ
studies of pLO-KO mice in vivo, wherein an initial worsening of
blood glucose levels was followed by subsequent stabilization of
glucoses at this slightly higher, but nondiabetic, level. In prior
studies, we and others have shown that an initial effect of cytokine
signaling (or STZ administration in vivo) is the upregulation of
iNOS, which leads to short-term defects in stimulus-secretion
coupling (19, 31, 41). Indeed, there is no evidence from our stud-
ies that this initial effect of cytokines is mitigated by loss of 12-LO.
FIG 7 Effect of 12-LO on Nrf2 levels in vitro and in vivo. Islets from 8-week-old control (fl/fl) and pLO-KO mice were isolated and treated with or without
cytokines and with or without 12-HETE for 24 h and processed for mRNA or protein (n	 3 per group). Pancreas sections from control and pLO-KOmice fed
a NCD or HFD for 20 weeks were immunostained for Nrf2. (A) Relative expression level ofNfe212mRNA in control and pLO-KOmouse islets (normalized to
Actb); (B) representative immunoblot from control and pLO-KO mouse islet extract for Nrf2 and histone 3; (C) quantitation of immunoblots (B) for Nrf2
protein normalized to histone 3 (n 	 3); (D) representative immunofluorescence images for Nrf2 (red) and insulin (green) (magnification, 
200); (E)
quantitation of the nuclear/cytoplasmic Nrf2 pixel density from islets of HFD-fed control and pLO-KO animals (n	 300 total insulin cells from three animals
per group). *, P 0.05 compared to control or comparisons indicated.
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These findings are unlikely to result from  cell loss in the 4- to
24-h period, since death of  cells does not occur until 24 h
incubationwith cytokines (42). Nevertheless, the longer-term sig-
naling effects of cytokines was clearly blunted in our studies. At
least two observations might account for this finding: first, it has
been reported that nitric oxide (the product of iNOS activity) can
increase substrate (nonesterified arachidonic acid) availability to
12-LO in  cells, resulting in increased 12-HETE production and
reduced stimulus-secretion coupling. Thus, in the absence of 12-
LO, this effect of nitric oxidewould be blunted. Second, it has been
shown that the longer term effects of cytokines include activation
of the UPR in  cells (42, 43). It is likely that these two observa-
tions are causally linked by 12-HETE. In this respect, our obser-
vations that 12-HETE activates the UPR in  cell lines despite
12-LO deletion suggests a role for 12-LO-derived lipid peroxides
in the development of islet ER stress in vitro.
The development of ER stress is closely linked to processes that
promote production of ROS (36). We show that whereas cyto-
kines can lead to increased  cell ROS in islets, at least part of this
effect can be attributed to 12-LO activity because its elimination
diminishes ROS production. 12-LO activity, particularly 12-
HETE itself, can increase NADPH oxidase activity in  cell lines,
with concomitant production of ROS, superoxide, and hydrogen
peroxide (35). The protection fromHFD-induced  cell dysfunc-
tion in pLO-KOmice likely reflects this reduction in ROS produc-
tion, since we observed dramatically reduced 4-HNE staining in
islets from these mice. Therefore, we feel our studies provide im-
portant new insights, since we demonstrate that 12-LO deletion
enhances the expression of antioxidant proteins Gpx1 and SOD1
and therefore may improve the  cell capacity to remediate oxi-
dative stress. In this context, the overexpression ofGpx1 in islets of
db/db diabetic mice protect against long-term hyperglycemia,
partly through the restoration of cell transcription factor expres-
sion (44, 45).
Because of the increases in Gpx1 and SOD1 in pLO-KO mice,
we considered the possibility that 12-LO and its product 12-HETE
affect the levels and/or nuclear localization of the transcription
factor Nrf2, which regulates the primary gene expression program
in response to oxidative stress (46). The  cell-specific Nrf2
knockout mouse exhibits enhanced sensitivity to oxidative stress
(47). Nrf2 is normally sequestered in the cytoplasm by two pro-
teins, Cul3 and Keap1, that lead to its ubiquitin-mediated degra-
dation. In the setting of oxidative stress, key cysteine residues in
Keap1 are oxidized, causing disruption of ubiquitination and ac-
cumulation of Nrf2 in both the cytoplasm and the nucleus (48–
50). In islets, we show that total Nrf2 levels are reduced by cyto-
kine incubation and restored upon the deletion of 12-LO. The
effect of cytokines is recapitulated with 12-HETE alone.We there-
fore believe that 12-HETE is the key factor linking 12-LO to Nrf2.
Similarly, we observed in pancreas sections of HFD-fed pLO-KO
mice that not only do the Nrf2 levels in  cells appear to increase
but also that the perinuclear staining of Nrf2 is enhanced.
Whether this effect on Nrf2 is a direct consequence of 12-HETE
effects on Nrf2 itself or upon its regulatory proteins is an ongoing
area of investigation in our group.
Taken together, our studies provide the first evidence that an
intrinsic action of 12-LO in islets is central to insulin secretory
defects and the development of glucose intolerance in the setting
of obesity and insulin resistance. Our studies present a conceptu-
ally innovative approach to understanding how different meta-
bolically active tissues might be linked to one another by a single
protein in the setting of obesity and insulin resistance. Based on
the data presented here, we propose the model depicted in Fig. 8.
In the setting of HFDs, cytokine signaling, and likely hyperglyce-
mia from impaired peripheral glucose uptake and elevated sys-
temic free fatty acids as well, promotes nitric oxide production
and stimulates 12-LO activity. As the former provides added sub-
strate to the latter, the intracellular production of lipid peroxide
intermediates (e.g., 12-HETE) is increased. 12-HETE promotes
oxidative stress and inhibits Nrf2 function, the result of which is
diminished stimulus-secretion coupling and eventual cell apop-
tosis. Undoubtedly, aspects of this model will require further re-
finement, since the mechanisms by which 12-HETE impacts Nrf2
remain unclear. The recent identification of a potential 12-HETE
receptor (GPR31 [51]) raises the possibility that these and other
effects of 12-HETE aremediated through a precise signaling path-
way involving G protein-coupled receptors. Nevertheless, our
studies suggest that the inhibition of 12-LO, possibly through clin-
ical application of recently identified selective inhibitors (52),may
have applicability in the preservation of islet  cell function in
prediabetes or established type 2 diabetes.
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